A Randomized Parallel-Group Study to Evaluate the Efficacy and Safety of I mmunotherapy for Idiopathic Cerebellar Ataxia - A Randomized Parallel-Group Study to Evaluate the Efficacy and Safety of I mmunotherapy for Idiopathic Cerebellar Ataxia

Department of Neurology, Gifu University Hospital0 个研究点目标入组 20 人开始时间: 2021年11月24日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•- already included in another trial which includes any intervention study - Those with a confirmed genetic diagnosis of hereditary spinocerebellar degeneration or those with a strong suspicion of hereditary origin - Those with a history of alcoholism or drug abuse - Use of medications that are likely to cause lightheadedness or cerebellar ataxia at the time of consent (e.g., antiepileptic drugs, benzodiazepines) - Those who are mentally disabled at the time of obtaining consent - Previous or currently treated stomach ulcers - Untreated or poorly controlled diabetes at the time of consent - Persons with severe hepatic or renal impairment at the time of obtaining consent - If you are pregnant or hoping to become pregnant at the time of obtaining consent - Dementia at the time of consent - At the time of obtaining consent, the patient is taking steroids or immunosuppressive drugs - Those taking antiplatelet or anticoagulant drugs that cannot be stopped at the time of obtaining consent - At the time of obtaining consent, the patient has an infectious disease that may be aggravated by steroids - Other items deemed inappropriate by the principal investigator/associate

发起方

Department of Neurology, Gifu University Hospital